GZR101 vs IcoSema
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
GZR101
Developed by Gan & Lee Pharmaceuticals
NCT06199505 · Phase 2 · completed
The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07387003 (registry estimate)
Reported efficacy
Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)
Result source: NCT06199505
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
Reported efficacy
Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)
Result source: NCT06269107
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GZR101 | IcoSema |
|---|---|---|
| HbA1c, change | -1.6% vs -1.3%avs IDegAsp once-dailyNCT061995052 other results
| -1.6% vs -0.9%vs Insulin IcodecNCT053528152 other results
|
| Body weight, change (kg) | —Not reported | -3.7 vs 2.0vs Insulin IcodecNCT053528151 other result
|
| HbA1c below 7% | —Not reported | —Not posted · NCT05013229 |
| Fasting plasma glucose, change | —Not reported | -1.9 vs -1.6vs Insulin IcodecNCT053528151 other result
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05013229 |
HbA1c, change
- GZR101
- -1.6% vs -1.3%avs IDegAsp once-dailyNCT06199505
2 other results
- -1.6% vs -1.6% NCT06199505
- -1.7% vs -1.6% NCT06199505
- IcoSema
- -1.6% vs -0.9%vs Insulin IcodecNCT05352815
2 other results
- -1.4% vs -0.9% NCT05259033
- -1.5% vs -1.4% NCT05013229
Body weight, change (kg)
- GZR101
- —Not reported
- IcoSema
- -3.7 vs 2.0vs Insulin IcodecNCT05352815
1 other result
- 0.9 vs -3.8 NCT05259033
HbA1c below 7%
- GZR101
- —Not reported
- IcoSema
- —Not posted · NCT05013229
Fasting plasma glucose, change
- GZR101
- —Not reported
- IcoSema
- -1.9 vs -1.6vs Insulin IcodecNCT05352815
1 other result
- -2.7 vs -1.4 NCT05259033
3-point MACE (% with event)
- GZR101
- —Not reported
- IcoSema
- —Not posted · NCT05013229
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. GZR101: 0 of 4 rows · IcoSema: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | GZR101 | IcoSema |
|---|---|---|
| Dropout rate | — | 5.4% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result3.8% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | — | — NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result— NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Serious AEs | — | 9.2% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | — | nausea 23.8% diarrhoea 15.8% vomiting 10.6% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more resultcovid-19 15% nausea 11.7% diarrhoea 11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
IcoSema
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · IcoSema's landscape